CSRC approves Lianya Pharmaceutical's IPO registration on the Shenzhen Stock Exchange.

On July 24th, the China Securities Regulatory Commission issued a reply approving the initial public offering of shares by Nantong Lianya Pharmaceutical Co., Ltd. It is reported that Lianya Pharmaceutical is listed on the Shenzhen Stock Exchange, with CICC as the sponsoring institution, planning to raise 950 million yuan. The prospectus shows that Lianya Pharmaceutical is a research-driven high-tech enterprise, mainly engaged in the research, production, and sales of complex drug formulations. Currently, its products mainly include two categories of high-end generic drugs represented by different types of sustained-release formulations and low-dose drug formulations. As of March 31, 2026, the company has completed the research and development of multiple products based on 6 major technology platforms independently developed, with 48 self-developed products approved by the US FDA in overseas markets, and 1 product approved in Canada. Indications include hypertension, coronary heart disease, diabetes, and female contraception. According to the statistics of Zhushi Consulting, as of the end of the reporting period, the company ranks third in the total number of oral formulations approved by the FDA for registration, ranks first in the number of oral sustained-release formulations approved by the FDA, and ranks first in the number of self-developed reference standard formulations (RS) approved by the FDA in China. Several sustained-release formulations have the highest market share in the US market.